Guangdong Hengrui Pharmaceutical Co., Ltd
PharmaGuangzhou, Guangdong, China · Est. 2000
Guangdong Hengrui Pharmaceutical is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative drugs.
8
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
10
Indications↗
Distinct diseases across all programs
69
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
8 drugs in development
Phase 34
Phase 25
Phase 11
By Therapeutic Area
top 5
Respiratory
545%
Immunology
327%
Dermatology
19%
Nephrology
19%
Hematology
19%
R&D Momentum
69/100
Pipeline Velocity
51/100
Trial Completion Rate
96/100
Pipeline Concentration
31/100
Pipeline Freshness
90/100
Strategic Signals
- ↗Active in Dermatology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Oct 23, 2026
Active, not recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Oct 23, 2026
Recruiting
A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of SHR-2173 in Patients With Generalized Myasthenia Gravis
Earlier
Sep 30, 2026TrialA Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Systemic Lupus Erythematosus
Sep 26, 2026TrialA Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injection or Intravenous Infusion of SHR-7590 Injection in Healthy Chinese Participants and Participants With Moderate-to-Severe Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease)
Sep 22, 2026TrialStudy on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
Sep 18, 2026TrialA Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SHR-1179 Injection in Obese Participants."
Sep 10, 2026TrialA Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
Sep 9, 2026TrialA Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
4 more events
Sep 4, 2026TrialA Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis
Sep 1, 2026TrialA Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
Aug 28, 2026TrialA Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Aug 25, 2026TrialA Randomized, Open-Label, Parallel-Group Clinical Study to Evaluate the Bioavailability and Safety of Subcutaneous SHR-1819 Injection Administered Using Different Injection Devices in Healthy Subjects
Details
Company Info
Therapeutic Focus
OncologyCardiovascularAnti-infection
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Dermatology
Hematology
Immunology
Dermatology
Prurigo Nodularis
SHR-1819Phase 3
Hematology
Immunology
Nephrology
Respiratory
Pulmonary Fibrosis
HRS-9813Phase 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)